1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014

Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 38 pages

Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014’, provides an overview of the Grupo Ferrer Internacional, S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grupo Ferrer Internacional, S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Grupo Ferrer Internacional, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Grupo Ferrer Internacional, S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Grupo Ferrer Internacional, S.A.’s pipeline products

Reasons to buy

- Evaluate Grupo Ferrer Internacional, S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Grupo Ferrer Internacional, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Grupo Ferrer Internacional, S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Grupo Ferrer Internacional, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grupo Ferrer Internacional, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Grupo Ferrer Internacional, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Grupo Ferrer Internacional, S.A. - Product Pipeline Review - 2014
Table of Contents
Grupo Ferrer Internacional, S.A. Snapshot 5
Grupo Ferrer Internacional, S.A. Overview 5
Key Information 5
Key Facts 5
Grupo Ferrer Internacional, S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Grupo Ferrer Internacional, S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Grupo Ferrer Internacional, S.A. - Pipeline Products Glance 13
Grupo Ferrer Internacional, S.A. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Grupo Ferrer Internacional, S.A. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Grupo Ferrer Internacional, S.A. - Drug Profiles 16
ozenoxacin 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
arasertaconazole 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
lorediplon 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
FIB-111 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
FIB-112 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
FIB-114 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
FIB-116 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
FIB-117 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Drugs for Bacterial Infections 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Drugs to Target Orexin Receptor for Narcolepsy and Sleep Disorders 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Malaria Program 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Grupo Ferrer Internacional, S.A. - Pipeline Analysis 28
Grupo Ferrer Internacional, S.A. - Pipeline Products by Target 28
Grupo Ferrer Internacional, S.A. - Pipeline Products by Route of Administration 29
Grupo Ferrer Internacional, S.A. - Pipeline Products by Molecule Type 30
Grupo Ferrer Internacional, S.A. - Pipeline Products by Mechanism of Action 31
Grupo Ferrer Internacional, S.A. - Recent Pipeline Updates 32
Grupo Ferrer Internacional, S.A. - Dormant Projects 34
Grupo Ferrer Internacional, S.A. - Locations And Subsidiaries 35
Head Office 35
Other Locations and Subsidiaries 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables

Grupo Ferrer Internacional, S.A., Key Information 5
Grupo Ferrer Internacional, S.A., Key Facts 5
Grupo Ferrer Internacional, S.A. - Pipeline by Indication, 2014 8
Grupo Ferrer Internacional, S.A. - Pipeline by Stage of Development, 2014 9
Grupo Ferrer Internacional, S.A. - Monotherapy Products in Pipeline, 2014 10
Grupo Ferrer Internacional, S.A. - Partnered Products in Pipeline, 2014 11
Grupo Ferrer Internacional, S.A. - Partnered Products/ Combination Treatment Modalities, 2014 12
Grupo Ferrer Internacional, S.A. - Phase III, 2014 13
Grupo Ferrer Internacional, S.A. - Phase II, 2014 14
Grupo Ferrer Internacional, S.A. - Discovery, 2014 15
Grupo Ferrer Internacional, S.A. - Pipeline by Target, 2014 28
Grupo Ferrer Internacional, S.A. - Pipeline by Route of Administration, 2014 29
Grupo Ferrer Internacional, S.A. - Pipeline by Molecule Type, 2014 30
Grupo Ferrer Internacional, S.A. - Pipeline Products by Mechanism of Action, 2014 31
Grupo Ferrer Internacional, S.A. - Recent Pipeline Updates, 2014 32
Grupo Ferrer Internacional, S.A. - Dormant Developmental Projects,2014 34
Grupo Ferrer Internacional, S.A., Other Locations 35
Grupo Ferrer Internacional, S.A., Subsidiaries 36

List of Figures

Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Indication, 2014 7
Grupo Ferrer Internacional, S.A. - Pipeline by Stage of Development, 2014 9
Grupo Ferrer Internacional, S.A. - Monotherapy Products in Pipeline, 2014 10
Grupo Ferrer Internacional, S.A. - Partnered Products in Pipeline, 2014 11
Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Target, 2014 28
Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Route of Administration, 2014 29
Grupo Ferrer Internacional, S.A. - Pipeline by Top 10 Molecule Type, 2014 30
Grupo Ferrer Internacional, S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.